JD Vance Predicts: Wall Street vs. Trump & Your Money

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

Jeffrey W. Albers net worth and biography

Jeffrey Albers Biography and Net Worth

Director of Kymera Therapeutics

Jeff has more than 20 years of experience working in the biopharmaceutical industry and bringing important new medicines to patients with cancer and rare diseases. From 2014 to 2022, Jeff served as Chief Executive Officer and Director of Blueprint Medicines, where he led the research-stage company through an initial public offering and evolved it into a leading precision medicine company with a global, fully integrated business, including two FDA-approved therapies and a rapidly advancing pipeline. Jeff previously served as President of Algeta, where he oversaw the successful commercial launch of a targeted cancer therapy prior to the company’s acquisition by Bayer. Prior to Algeta, he held senior commercial and corporate development positions at Genzyme (now a division of Sanofi), including vice president of the U.S. hematology and oncology business unit. Earlier in his career, Jeff was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University. He is currently board chairman of Blueprint Medicines and is on the board of directors of Kymera Therapeutics. Additionally, Jeff is a Venture Partner at Atlas Venture and serves on the board of advisors for Life Sciences Cares.

What is Jeffrey W. Albers' net worth?: The estimated net worth of Jeffrey W. Albers is at least $1.50 million as of October 25th, 2024. Mr. Albers owns 34,060 shares of Kymera Therapeutics stock worth more than $1,500,343 as of November 20th. This net worth approximation does not reflect any other investments that Mr. Albers may own. Learn More about Jeffrey W. Albers' net worth.
How do I contact Jeffrey W. Albers?: The corporate mailing address for Mr. Albers and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected]. Learn More on Jeffrey W. Albers' contact information.
Has Jeffrey W. Albers been buying or selling shares of Kymera Therapeutics?: Jeffrey W. Albers has not been actively trading shares of Kymera Therapeutics over the course of the past ninety days. Learn More on Jeffrey W. Albers' trading history.
Who are Kymera Therapeutics' active insiders?: Kymera Therapeutics' insider roster includes Jeffrey Albers (Director), Bruce Booth (Director), Richard Chesworth (Insider), Ellen Chiniara (Chief Legal Officer and Corporate Secretary), Jared Gollob (Insider), Bruce Jacobs (CFO), and Nello Mainolfi (CEO). Learn More on Kymera Therapeutics' active insiders.
Are insiders buying or selling shares of Kymera Therapeutics?: In the last twelve months, insiders at the sold shares 16 times. They sold a total of 1,008,191 shares worth more than $40,176,324.03. The most recent insider tranaction occured on September, 17th when Director Pamela Esposito sold 13,500 shares worth more than $651,780.00. Insiders at Kymera Therapeutics own 15.8% of the company. Learn More about insider trades at Kymera Therapeutics.
Information on this page was last updated on 9/17/2024.

Jeffrey W. Albers Insider Trading History at Kymera Therapeutics

Jeffrey W. Albers Buying and Selling Activity at Kymera Therapeutics

Kymera Therapeutics Company Overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $43.83

$43.83

$44.38

50 Day Range

MA: $47.00

$41.96

$52.40

2 Week Range

Now: $43.83

$18.89

$53.27

Volume

1,074 shs

Average Volume

584,563 shs

Market Capitalization

$2.84 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.21

Tesla Execs are Freaking Out

From Angel Publishing | Ad

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Click here to get the details.